The journal focuses on all topics related to hepatoma, including its occurrence, development, diagnosis, and treatment. The coverage also extends to other basic and clinical studies related to statistics, epidemiology, public health, surgery, internal medicine, cell biology, pathology, pathophysiology, immunology, genetics, pharmacology, etc. Carcinogenic mechanism of hepatoma, especially the role of HBV evolution on the development of hepatocellular carcinoma; Development of diagnostic, prognostic, and predictive biomarkers for hepatocellular carcinoma and biliary tract cancer; Therapeutic options of hepatoma as well as complications of hepatoma including basic and clinical research on animal models, liver transplantation, molecular targeted therapy, immunotherapy, interventional therapy, hepatoma treatment-related drugs, as well as clinical transition of the latest laboratory therapy; Epidemiology of liver cancer and biliary tract cancer: including risk factors of liver cancer and biliary tract cancer, statistics, survival and prognosis, predictive risk models, active prophylaxis of liver cancer and biliary tract cancer. Cohort study and randomized controlled clinical trial are particularly welcome. The journal publishes the following types of articles: Original Article, Review, Systematic Review, Meta-analysis, Case Report, Commentary, Editorial, Research Highlight, etc..
Hepatoma Research, 2394-5079 /-, started opeartions from United States in year 2015, publish paper in Medicine (General) Monthly.